TSX:CURAPharmaceuticals
Curaleaf (TSX:CURA) Valuation Check After U.S. Cannabis Rescheduling Boosts Growth Optimism
Curaleaf Holdings (TSX:CURA) is back in the spotlight after the Trump Administration moved to reclassify cannabis as a Schedule III substance. This policy shift could reshape taxes, research access, and long term profitability.
See our latest analysis for Curaleaf Holdings.
Even after a sharp 1 week share price pullback and a 1 day dip to around CA$4.14, Curaleaf still boasts an 80% year to date share price return and a 95.28% 1 year total shareholder return. This suggests momentum is cooling...